Avecho has announced that it has signed an exclusive 10-year development and licensing agreement with Sandoz Group AG for the commercial rights to Avecho’s Phase III CBD capsule for insomnia in Australia.
Under the deal, Avecho will receive a US$3M upfront licensing fee for the exclusive commercial rights in Australia, development milestone payments totalling US$16M prior to commercialisation, and royalties on net sales once on market. Avecho retains the rights to commercialise the product in all other territories, with Sandoz granted a first right of refusal for these markets.
Wonder what what's her name thinks? Greedy Bitch!
Avecho has announced that it has signed an exclusive 10-year...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
0.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $15.86M | |||
| Open | High | Low | Value | Volume |
| 0.5¢ | 0.5¢ | 0.5¢ | $19.24K | 3.848M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 92066 | 0.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.6¢ | 8239699 | 10 |
View Market Depth
| Last trade - 11.27am 31/07/2025 (20 minute delay) ? |
| AVE (ASX) Chart |